TY - JOUR
T1 - The potential of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis and management of patients with brain tumors
AU - Leclerc, Xavier
AU - Huisman, Thierry A G M
AU - Sorensen, A. Gregory
PY - 2002
Y1 - 2002
N2 - Proton (1H) magnetic resonance spectroscopy (MRS) is a noninvasive method that can monitor the metabolic changes in most brain diseases. This technique is now available on current 1.5 Tesla magnetic resonance units and does not require sophisticated software or time-consuming post-processing techniques. Previous studies using single-voxel techniques showed the usefulness of MRS for the diagnosis of brain tumor despite some technical issues, including spatial resolution and volume coverage. Recent advances have been made through the use of multivoxel techniques and metabolite maps, which allow assessment of both the entire volume of the lesion and the surrounding normal-appearing brain tissue. Recent studies suggest the potential of this technique to guide biopsies, to define radiotherapy targets, and to monitor patients after treatment. Some persistent drawbacks, including measurement time and spectral resolution, will probably be overcome in the near future.
AB - Proton (1H) magnetic resonance spectroscopy (MRS) is a noninvasive method that can monitor the metabolic changes in most brain diseases. This technique is now available on current 1.5 Tesla magnetic resonance units and does not require sophisticated software or time-consuming post-processing techniques. Previous studies using single-voxel techniques showed the usefulness of MRS for the diagnosis of brain tumor despite some technical issues, including spatial resolution and volume coverage. Recent advances have been made through the use of multivoxel techniques and metabolite maps, which allow assessment of both the entire volume of the lesion and the surrounding normal-appearing brain tissue. Recent studies suggest the potential of this technique to guide biopsies, to define radiotherapy targets, and to monitor patients after treatment. Some persistent drawbacks, including measurement time and spectral resolution, will probably be overcome in the near future.
UR - http://www.scopus.com/inward/record.url?scp=0036245455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036245455&partnerID=8YFLogxK
U2 - 10.1097/00001622-200205000-00007
DO - 10.1097/00001622-200205000-00007
M3 - Article
C2 - 11981274
AN - SCOPUS:0036245455
SN - 1040-8746
VL - 14
SP - 292
EP - 298
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 3
ER -